Increased Fatty Acid Synthase Expression and Activity During Progression of Prostate Cancer in the TRAMP Model

Beth Pflug, Stefana M. Pecher, Alisa W. Brink, Joel B. Nelson, Barbara A. Foster

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

BACKGROUND. Fatty acid synthase (FAS) is the major enzyme required to convert carbohydrates to fatty acids. Recent evidence suggests that FAS activity is essential for prostate cancer growth and survival, since blocking the enzyme activity results in cell death. In this study, the role of FAS up-regulation during prostate tumor progression in the transgenic adenocarcinoma of mouse prostate (TRAMP) model was investigated. Sensitivity to FAS antimetabolites was also analyzed in TRAMP prostate tumor cells and tissue to determine therapeutic potential of FAS inhibition in the treatment of prostate cancer. METHODS. FAS expression was evaluated by immunohistochemistry of TRAMP tissues, including primary and metastatic lesions in mice of varying ages. FAS pathway activity was studied in vitro using TRAMP-derived cell lines and in vivo in TRAMP tissues. The sensitivity of TRAMP cell lines and tissues to the antimetabolite drugs (2R,3S)-2,3-epoxy-4-oxo-7,10-trans, transdodecadienamide (cerulenin) and C-75, which target FAS, was determined by FAS antimetabolite inhibition of 14C-acetate conversion to fatty acids, cell growth inhibition, and apoptosis analyses. RESULTS. High FAS expression and activity in the TRAMP mouse prostate was evident at 12 weeks of age compared with nontransgenic littermates and further increased with age, tumor progression, and in metastatic lesions. FAS pathway inhibition resulted in a dose-dependent reduction in cell survival and decreased enzyme activity in these models. CONCLUSIONS. These data suggest that the up-regulation of FAS expression play a role in tumorigenesis of the prostate in the TRAMP model and hence can provide valuable insight into human prostate cancer. Given the response of tumor cells to FAS antimetabolites, FAS may serve as a novel target for prostate cancer therapy.

Original languageEnglish (US)
Pages (from-to)245-254
Number of pages10
JournalProstate
Volume57
Issue number3
DOIs
StatePublished - Nov 1 2003
Externally publishedYes

Fingerprint

Fatty Acid Synthases
Transgenic Mice
Prostate
Prostatic Neoplasms
Adenocarcinoma
Antimetabolites
Neoplasms
Up-Regulation
Enzymes
Fatty Acids
Cerulenin
Cell Line
Growth

Keywords

  • FAS anti-metabolites
  • Fatty acid synthase
  • Prostate cancer
  • TRAMP model
  • Tumor progression

ASJC Scopus subject areas

  • Urology

Cite this

Increased Fatty Acid Synthase Expression and Activity During Progression of Prostate Cancer in the TRAMP Model. / Pflug, Beth; Pecher, Stefana M.; Brink, Alisa W.; Nelson, Joel B.; Foster, Barbara A.

In: Prostate, Vol. 57, No. 3, 01.11.2003, p. 245-254.

Research output: Contribution to journalArticle

Pflug, Beth ; Pecher, Stefana M. ; Brink, Alisa W. ; Nelson, Joel B. ; Foster, Barbara A. / Increased Fatty Acid Synthase Expression and Activity During Progression of Prostate Cancer in the TRAMP Model. In: Prostate. 2003 ; Vol. 57, No. 3. pp. 245-254.
@article{fbd0f9d4e10c4954b00a1e6f56668d8e,
title = "Increased Fatty Acid Synthase Expression and Activity During Progression of Prostate Cancer in the TRAMP Model",
abstract = "BACKGROUND. Fatty acid synthase (FAS) is the major enzyme required to convert carbohydrates to fatty acids. Recent evidence suggests that FAS activity is essential for prostate cancer growth and survival, since blocking the enzyme activity results in cell death. In this study, the role of FAS up-regulation during prostate tumor progression in the transgenic adenocarcinoma of mouse prostate (TRAMP) model was investigated. Sensitivity to FAS antimetabolites was also analyzed in TRAMP prostate tumor cells and tissue to determine therapeutic potential of FAS inhibition in the treatment of prostate cancer. METHODS. FAS expression was evaluated by immunohistochemistry of TRAMP tissues, including primary and metastatic lesions in mice of varying ages. FAS pathway activity was studied in vitro using TRAMP-derived cell lines and in vivo in TRAMP tissues. The sensitivity of TRAMP cell lines and tissues to the antimetabolite drugs (2R,3S)-2,3-epoxy-4-oxo-7,10-trans, transdodecadienamide (cerulenin) and C-75, which target FAS, was determined by FAS antimetabolite inhibition of 14C-acetate conversion to fatty acids, cell growth inhibition, and apoptosis analyses. RESULTS. High FAS expression and activity in the TRAMP mouse prostate was evident at 12 weeks of age compared with nontransgenic littermates and further increased with age, tumor progression, and in metastatic lesions. FAS pathway inhibition resulted in a dose-dependent reduction in cell survival and decreased enzyme activity in these models. CONCLUSIONS. These data suggest that the up-regulation of FAS expression play a role in tumorigenesis of the prostate in the TRAMP model and hence can provide valuable insight into human prostate cancer. Given the response of tumor cells to FAS antimetabolites, FAS may serve as a novel target for prostate cancer therapy.",
keywords = "FAS anti-metabolites, Fatty acid synthase, Prostate cancer, TRAMP model, Tumor progression",
author = "Beth Pflug and Pecher, {Stefana M.} and Brink, {Alisa W.} and Nelson, {Joel B.} and Foster, {Barbara A.}",
year = "2003",
month = "11",
day = "1",
doi = "10.1002/pros.10297",
language = "English (US)",
volume = "57",
pages = "245--254",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Increased Fatty Acid Synthase Expression and Activity During Progression of Prostate Cancer in the TRAMP Model

AU - Pflug, Beth

AU - Pecher, Stefana M.

AU - Brink, Alisa W.

AU - Nelson, Joel B.

AU - Foster, Barbara A.

PY - 2003/11/1

Y1 - 2003/11/1

N2 - BACKGROUND. Fatty acid synthase (FAS) is the major enzyme required to convert carbohydrates to fatty acids. Recent evidence suggests that FAS activity is essential for prostate cancer growth and survival, since blocking the enzyme activity results in cell death. In this study, the role of FAS up-regulation during prostate tumor progression in the transgenic adenocarcinoma of mouse prostate (TRAMP) model was investigated. Sensitivity to FAS antimetabolites was also analyzed in TRAMP prostate tumor cells and tissue to determine therapeutic potential of FAS inhibition in the treatment of prostate cancer. METHODS. FAS expression was evaluated by immunohistochemistry of TRAMP tissues, including primary and metastatic lesions in mice of varying ages. FAS pathway activity was studied in vitro using TRAMP-derived cell lines and in vivo in TRAMP tissues. The sensitivity of TRAMP cell lines and tissues to the antimetabolite drugs (2R,3S)-2,3-epoxy-4-oxo-7,10-trans, transdodecadienamide (cerulenin) and C-75, which target FAS, was determined by FAS antimetabolite inhibition of 14C-acetate conversion to fatty acids, cell growth inhibition, and apoptosis analyses. RESULTS. High FAS expression and activity in the TRAMP mouse prostate was evident at 12 weeks of age compared with nontransgenic littermates and further increased with age, tumor progression, and in metastatic lesions. FAS pathway inhibition resulted in a dose-dependent reduction in cell survival and decreased enzyme activity in these models. CONCLUSIONS. These data suggest that the up-regulation of FAS expression play a role in tumorigenesis of the prostate in the TRAMP model and hence can provide valuable insight into human prostate cancer. Given the response of tumor cells to FAS antimetabolites, FAS may serve as a novel target for prostate cancer therapy.

AB - BACKGROUND. Fatty acid synthase (FAS) is the major enzyme required to convert carbohydrates to fatty acids. Recent evidence suggests that FAS activity is essential for prostate cancer growth and survival, since blocking the enzyme activity results in cell death. In this study, the role of FAS up-regulation during prostate tumor progression in the transgenic adenocarcinoma of mouse prostate (TRAMP) model was investigated. Sensitivity to FAS antimetabolites was also analyzed in TRAMP prostate tumor cells and tissue to determine therapeutic potential of FAS inhibition in the treatment of prostate cancer. METHODS. FAS expression was evaluated by immunohistochemistry of TRAMP tissues, including primary and metastatic lesions in mice of varying ages. FAS pathway activity was studied in vitro using TRAMP-derived cell lines and in vivo in TRAMP tissues. The sensitivity of TRAMP cell lines and tissues to the antimetabolite drugs (2R,3S)-2,3-epoxy-4-oxo-7,10-trans, transdodecadienamide (cerulenin) and C-75, which target FAS, was determined by FAS antimetabolite inhibition of 14C-acetate conversion to fatty acids, cell growth inhibition, and apoptosis analyses. RESULTS. High FAS expression and activity in the TRAMP mouse prostate was evident at 12 weeks of age compared with nontransgenic littermates and further increased with age, tumor progression, and in metastatic lesions. FAS pathway inhibition resulted in a dose-dependent reduction in cell survival and decreased enzyme activity in these models. CONCLUSIONS. These data suggest that the up-regulation of FAS expression play a role in tumorigenesis of the prostate in the TRAMP model and hence can provide valuable insight into human prostate cancer. Given the response of tumor cells to FAS antimetabolites, FAS may serve as a novel target for prostate cancer therapy.

KW - FAS anti-metabolites

KW - Fatty acid synthase

KW - Prostate cancer

KW - TRAMP model

KW - Tumor progression

UR - http://www.scopus.com/inward/record.url?scp=0142106795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142106795&partnerID=8YFLogxK

U2 - 10.1002/pros.10297

DO - 10.1002/pros.10297

M3 - Article

VL - 57

SP - 245

EP - 254

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 3

ER -